Last reviewed · How we verify
Docetaxol
Docetaxol is a Small molecule drug developed by Fudan University. It is currently in Phase 2 development for Carcinoma of breast, Malignant tumor of head and/or neck, Malignant tumor of prostate.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Docetaxol |
|---|---|
| Sponsor | Fudan University |
| Target | Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Approved indications
- Carcinoma of breast
- Malignant tumor of head and/or neck
- Malignant tumor of prostate
- Malignant tumor of stomach
- Metastatic Breast Carcinoma
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Severe neutropenia
- Febrile Neutropenia
- Severe infectious episodes
- Thrombocytopenia
- Hypersensitivity Reactions
- Fluid Retention
- Neurosensory
- Cutaneous
- Nail Changes
- Nausea
- Vomiting
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (PHASE3)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer (PHASE2)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxol CI brief — competitive landscape report
- Docetaxol updates RSS · CI watch RSS
- Fudan University portfolio CI
Frequently asked questions about Docetaxol
What is Docetaxol?
What is Docetaxol used for?
Who makes Docetaxol?
What development phase is Docetaxol in?
What are the side effects of Docetaxol?
What does Docetaxol target?
Related
- Target: All drugs targeting Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor
- Manufacturer: Fudan University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Carcinoma of breast
- Indication: Drugs for Malignant tumor of head and/or neck
- Indication: Drugs for Malignant tumor of prostate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing